Cargando…

Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas

SIMPLE SUMMARY: Dysregulated B-cell receptor (BCR) signaling is considered a potent contributor to tumor survival in different subtypes of B-cell non-Hodgkin lymphomas (B-NHLs). In the last decade, BCR-targeted therapies have emerged as promising alternative treatment options to standard chemoimmuno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Profitós-Pelejà, Núria, Santos, Juliana Carvalho, Marín-Niebla, Ana, Roué, Gaël, Ribeiro, Marcelo Lima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870007/ https://www.ncbi.nlm.nih.gov/pubmed/35205606 http://dx.doi.org/10.3390/cancers14040860

Ejemplares similares

Immune-Checkpoint Inhibitors in B-Cell Lymphoma
por: Armengol, Marc, et al.
Publicado: (2021)

Antitumor Activity of Simvastatin in Preclinical Models of Mantle Cell Lymphoma
por: Santos, Juliana Carvalho, et al.
Publicado: (2022)

RHOA Therapeutic Targeting in Hematological Cancers
por: Santos, Juliana Carvalho, et al.
Publicado: (2023)

G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2023)

Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2021)

Epigenetic targets in B- and T-cell lymphomas: latest developments
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2023)

Ikaros as a downstream mediator of BCR blockade therapy in B-cell non-Hodgkin lymphoma
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2022)

Editorial: The molecular landscape and promising therapeutic targets in aggressive B-cell non-Hodgkin lymphomas
por: Witte, Hanno Maximilian, et al.
Publicado: (2023)

Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma
por: Ribeiro, Marcelo L., et al.
Publicado: (2019)

Constitutive Activation of p62/Sequestosome-1-Mediated Proteaphagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell Lymphoma
por: Quinet, Grégoire, et al.
Publicado: (2022)

Aggressive B-Cell Lymphomas
por: Naresh, Kikkeri N., et al.
Publicado: (2012)

Management of Drug Resistance in Mantle Cell Lymphoma
por: Roué, Gaël, et al.
Publicado: (2020)

Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutation
por: Dlouhy, Ivan, et al.
Publicado: (2021)

Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutation
por: Dlouhy, Ivan, et al.
Publicado: (2022)

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications
por: Reyes-Garau, Diana, et al.
Publicado: (2019)

Novel Therapies for Aggressive B-Cell Lymphoma
por: Foon, Kenneth A., et al.
Publicado: (2012)

Molecular classification of aggressive B-cell lymphoma
por: Bojarczuk, Kamil, et al.
Publicado: (2019)

Microenvironment-Centred Dynamics in Aggressive B-Cell Lymphomas
por: Cacciatore, Matilde, et al.
Publicado: (2012)

Epigenetics, c-Myc and Aggressive B-cell Lymphomas
por: Zhang, Yizhuo, et al.
Publicado: (2012)

Biological Approaches to Aggressive Cutaneous B-Cell Lymphomas
por: Tadiotto Cicogna, Giulia, et al.
Publicado: (2019)

The International Prognostic Index in aggressive B-cell lymphoma
por: Maurer, Matthew J.
Publicado: (2023)

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
por: Kwon, Mi, et al.
Publicado: (2022)

Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma: An Underrecognized Aggressive Lymphoma
por: Morgan, Elizabeth A., et al.
Publicado: (2012)

Renal Lymphoma: Primary or First Manifestation of Aggressive Pediatric B-cell Lymphoma
por: Coca, Pragnya, et al.
Publicado: (2017)

Oncogenic Properties of Apoptotic Tumor Cells in Aggressive B Cell Lymphoma
por: Ford, Catriona A., et al.
Publicado: (2015)

Genetic background and evolution of relapses in aggressive B-cell lymphomas
por: Juskevicius, Darius, et al.
Publicado: (2017)

Aggressive B-cell lymphoma subtyping: a pathologists viewpoint
por: de Jong, Daphne
Publicado: (2019)

Relevant Cytokines in the B Cell Lymphoma Micro-Environment
por: Krause, Günter, et al.
Publicado: (2020)

A Patient With Regressed Diffuse Large B-Cell Lymphoma and Aggressive Follicular Lymphoma
por: Sethi, Ashish K, et al.
Publicado: (2021)

Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
por: Borgerding, Andrea, et al.
Publicado: (2009)

Stem cell characteristics promote aggressiveness of diffuse large B-cell lymphoma
por: Chang, Kung-Chao, et al.
Publicado: (2020)

Extranodal large B-cell type aggressive non-Hodgkin's lymphoma
por: Batra, Ranmeet, et al.
Publicado: (2014)

Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas
por: Gao, Jing, et al.
Publicado: (2021)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
por: Ortuzar Pasalodos, A., et al.
Publicado: (2022)

Primary Hepatosplenic Large B-Cell Lymphoma: A Rare Aggressive Tumor
por: Morales-Polanco, M.R., et al.
Publicado: (2008)

Bone Marrow Involvement by Aggressive B Cell Lymphoma Undetected by Aspirate Immunophenotyping
por: Moshref Razavi, Habib
Publicado: (2021)

Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas
por: Calvo-Vidal, M. Nieves, et al.
Publicado: (2021)

MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas
por: Wang, Michelle Y., et al.
Publicado: (2021)

BFL-1 expression determines the efficacy of venetoclax in MYC+/BCL2+ double hit lymphoma
por: Esteve-Arenys, Anna, et al.
Publicado: (2018)

High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients
por: Marino, Dario, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_002r4igng7ara7qrqb9hlcul0u